Added to YB: 2026-05-20
Pitch date: 2026-05-17
REGN [neutral]
Regeneron Pharmaceuticals, Inc.
-0.03%
current return
Author Info
Notes From The Beauty Contest is a buy-side investor who thought it might be fun to write about stocks in their spare time and in their own way. Sign up for the newsletter.
Company Info
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Market Cap
$71.0B
Pitch Price
$630.49
Price Target
N/A
Dividend
0.54%
EV/EBITDA
12.49
P/E
17.01
EV/Sales
3.70
Sector
Biotechnology
Category
growth
The NFTBC Digest (17 May 2026) - Regeneron Pharmaceuticals, Inc.
REGN (update): Fianlimab-cemiplimab combo in metastatic melanoma missed primary PFS endpoint (HR 0.845, CI crossed 1.0). Median PFS 11.5mo vs 6.4mo pembro (15.5% risk reduction fell short of expectations). Still awaits head-to-head vs Opdualag in ~10mo & OS data. Mgmt sees $2-3B market; downgrade timeline +1yr but not write-off yet.
Read full article (4 min)